KIT and kidney cancer: For example, imatinib and sunitinib, which are used on gastrointestinal stromal tumours (GISTs), simultaneously interrupt BCR-ABL, KIT, and PDGFR tyrosine kinase pathways, promoting cell cycle arrest [40, 41]; sorafenib inhibits the VEGFR, PDGFR, KIT, FLT3, and RAF pathways in late-stage kidney cancer [42].